Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences to partner Tango Therapeutics on targeted oncology treatments pipeline

Gilead Sciences to partner Tango Therapeutics on targeted oncology treatments pipeline

20th November 2018

Gilead Sciences, Inc. and Tango Therapeutics, Inc. are in partnership to discover, develop, and commercialize a pipeline of targeted immuno-oncology therapies. Tango will perform target discovery and validation, and Gilead will have options to worldwide rights on up to five targets emerging from Tango’s proprietary functional genomics-based discovery platform. For two programs directed to these targets, Tango will retain the option to co-develop and co-detail in the U.S. Tango’s lead programs are not included in this arrangement.
John McHutchison, AO, MD, Gilead’s chief scientific officer and head of R&D, said: “Tango has built a unique discovery platform that we hope will help create the next generation of cancer therapies. Our collaboration will combine Tango’s innovative discovery technology alongside Gilead’s drug discovery and development capabilities to build a pipeline of novel immuno-oncology therapies.”
Tango’s president and CEO, Barbara Weber, MD, said: “Gilead is the ideal partner to help us bring potentially transformative treatments to patients with cancer. This partnership has significant strategic value for us. With Gilead as our partner, we can maximize the applications of our platform in immuno-oncology, while continuing to independently advance our lead programs into the clinic and beyond.”

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.